Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:EXAS News 20 November 2025 - 2 February 2026

Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott Laboratories shares edged up 0.1% to $109.43 after Barclays cut its price target to $142 but kept an Overweight rating. Nutrition sales fell 8.9% last quarter, and diagnostics dropped 2.5%. Exact Sciences shareholders will vote February 20 on Abbott’s planned $23 billion takeover. The deal is expected to close in the second quarter of 2026.
2 February 2026
······
Abbott stock rebounds as Exact Sciences vote nears after broker upgrade

Abbott stock rebounds as Exact Sciences vote nears after broker upgrade

Abbott Laboratories shares rose 2.6% to $108.89 Friday after missing revenue targets and guiding first-quarter adjusted EPS below analyst estimates. Freedom Capital Markets upgraded the stock to “buy” but cut its price target. Abbott expects to close its $23 billion Exact Sciences acquisition by Q2 2026. Exact Sciences shareholders will vote on the merger Feb. 20.
30 January 2026
·····
Abbott stock price steadies near a 52-week low as upgrade talk meets nutrition worries

Abbott stock price steadies near a 52-week low as upgrade talk meets nutrition worries

Abbott Laboratories shares rose 0.3% to $106.34 Thursday after a broker upgrade, following sharp losses from missed revenue and a cautious outlook last week. The stock touched a 52-week low of $105.27. Abbott plans to acquire Exact Sciences for $105 per share, with a shareholder vote set for Feb. 20. The company declared a $0.63 quarterly dividend, payable Feb. 13.
29 January 2026
·····
Abbott stock rises after CEO Robert Ford buys $2 million in shares — what ABT investors watch next

Abbott stock rises after CEO Robert Ford buys $2 million in shares — what ABT investors watch next

Abbott Laboratories shares rose about 1.3% to close near $108.77 in after-hours trading Monday after CEO Robert B. Ford’s family trust bought 18,800 shares at roughly $107 each, according to an SEC filing. The move follows a sharp selloff last week after Abbott missed revenue estimates and issued a weak earnings outlook.
27 January 2026
·····
Abbott Laboratories stock (ABT) in focus: Exact Sciences vote date lands as earnings week nears

Abbott Laboratories stock (ABT) in focus: Exact Sciences vote date lands as earnings week nears

New York, January 11, 2026, 15:30 EST — Market closed. Abbott Laboratories starts the week with its proposed acquisition of Exact Sciences in the spotlight, following Exact Sciences’ announcement of a shareholder vote scheduled for Feb. 20. Timing is crucial here since Abbott’s quarterly results come out on Jan. 22. That report could reset expectations for 2026 and clarify just how much management plans to spend—and absorb—in pursuit of growth. Wall Street is tugging in opposite directions. Bernstein’s Lee Hambright nudged his price target up to $154 from $150. On the flip side, Goldman Sachs trimmed its target to $152
11 January 2026
······
Abbott stock today: ABT rises as Exact Sciences deal filing and Volt AFib device stay in focus

Abbott stock today: ABT rises as Exact Sciences deal filing and Volt AFib device stay in focus

NEW YORK, December 30, 2025, 19:51 ET — After-hours Abbott Laboratories (ABT.N) shares rose 0.97% to $125.78 in Tuesday’s regular session and held steady in after-hours trading. ABT quote The move lands as investors reprice 2026 catalysts for large-cap healthcare, where product cycles and deal timelines can matter more than day-to-day macro noise. Abbott has two big threads in play: a planned push deeper into cancer screening through a major acquisition and a newly cleared heart-rhythm device in a fast-developing market. Both can influence revenue mix and margins, which feed directly into valuation. In the broader tape, U.S. stocks ended
31 December 2025
····
Exact Sciences (EXAS) Stock: Abbott’s $23 Billion Deal, Q3 Earnings Beat and What Investors Should Watch Now

Exact Sciences (EXAS) Stock: Abbott’s $23 Billion Deal, Q3 Earnings Beat and What Investors Should Watch Now

Exact Sciences Corporation (NASDAQ: EXAS) has turned into one of the most closely watched healthcare stocks heading into December 2025, thanks to a blockbuster takeover agreement with Abbott Laboratories, strong Q3 results, and a rapid share‑price rally that has pushed EXAS to all‑time highs. As of mid‑day on December 1, 2025, the stock trades around $101 per share, just below the agreed $105 per‑share cash buyout price. Exact Sciences Investor Relations+1 Below is a deep dive into the latest news, earnings, analyst forecasts, and key risks around Exact Sciences stock as of December 1, 2025. Exact Sciences Stock Today: Trading
1 December 2025
·····
Exact Sciences (EXAS) Stock Today: Analyst Downgrades, Abbott’s $21 Billion Takeover and Legal Scrutiny – 25 November 2025

Exact Sciences (EXAS) Stock Today: Analyst Downgrades, Abbott’s $21 Billion Takeover and Legal Scrutiny – 25 November 2025

Exact Sciences Corporation (NASDAQ: EXAS) is trading near record highs as Wall Street shifts to “Hold,” merger-arb funds move in and shareholder lawyers start circling Abbott’s $21 billion bid. Exact Sciences Stock Price Snapshot for 25 November 2025 On Tuesday, 25 November 2025, Exact Sciences stock is trading around $101 per share, hovering just below its all‑time and 52‑week high near $102.ChartMill+1 That puts EXAS: At this point, EXAS is behaving less like a typical growth stock and more like a merger‑arbitrage trade: most of the upside is capped by the announced cash offer, while the remaining discount compensates investors
25 November 2025
·····
Exact Sciences (EXAS) Stock Today, November 24, 2025: Abbott Buyout Spread, Analyst Downgrades and UBS Target Hike

Exact Sciences (EXAS) Stock Today, November 24, 2025: Abbott Buyout Spread, Analyst Downgrades and UBS Target Hike

Dateline: November 24, 2025 Exact Sciences Corporation (NASDAQ: EXAS) stock is trading calmly near its takeover price today as Wall Street digests a flood of fresh analyst calls, legal scrutiny and local reaction to Abbott Laboratories’ multi‑billion‑dollar bid for the cancer‑diagnostics specialist. With shares hovering around $101 this afternoon and a cash offer on the table at $105 per share, Exact Sciences has effectively shifted from a high‑growth story to a merger‑arbitrage situation — but there’s still plenty happening around the name on November 24, 2025. Exact Sciences Investor Relations+1 Key takeaways for EXAS stock on November 24, 2025 Exact
24 November 2025
······
Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories (NYSE: ABT) shook the healthcare and medtech markets today, November 20, 2025, by announcing a definitive agreement to acquire cancer diagnostics specialist Exact Sciences Corporation (NASDAQ: EXAS) in an all‑cash transaction valuing the target at about $21 billion in equity and roughly $23 billion including debt. Reuters+2PR Newswire+2 The move marks Abbott’s largest acquisition in nearly a decade and one of the biggest healthcare deals of 2025, instantly positioning the company as a heavyweight in cancer screening and precision oncology diagnostics — markets it has largely approached from the sidelines until now. Reuters+1 As of mid‑afternoon trading, ABT
20 November 2025
······
Abbott to Acquire Exact Sciences for $21 Billion in Cancer Screening Mega-Deal

Abbott to Acquire Exact Sciences for $21 Billion in Cancer Screening Mega-Deal

Abbott has agreed to acquire cancer diagnostics specialist Exact Sciences in a cash deal valued at about $21 billion in equity, or roughly $23 billion including debt, in one of the biggest healthcare transactions of 2025 and Abbott’s largest deal in nearly a decade. Abbott MediaRoom+2Reuters+2 The transaction gives Abbott an immediate leadership position in fast‑growing cancer screening and precision oncology diagnostics, anchored by Exact Sciences’ flagship tests Cologuard and Oncotype DX, plus its new multi‑cancer blood test Cancerguard. Abbott MediaRoom+2investor.exactsciences.com+2 Deal Terms: $105 per Share and a $23 Billion Enterprise Value Under the definitive agreement announced today, Abbott will
20 November 2025
······

Stock Market Today

Diageo share price slips into the weekend as investors eye Feb. 25 results

Diageo share price slips into the weekend as investors eye Feb. 25 results

7 February 2026
Diageo shares closed down 1.48% at 1,760 pence on Friday, trailing a 0.59% gain in the FTSE 100. An updated analyst consensus points to a 2.0% fall in first-half organic net sales ahead of interim results due Feb. 25. Trading volume was light, and the stock remains over 22% below its 52-week high.
National Grid share price: what to know before London reopens after BoE signal

National Grid share price: what to know before London reopens after BoE signal

7 February 2026
National Grid shares closed at 1,285 pence in London on Friday, up 0.23%. The Bank of England held rates at 3.75% after a close vote, signaling possible cuts if inflation falls. National Grid announced a wireless power transmission study with Space Solar and marked five years of IFA2 interconnector operations. Its U.S. ADR ended at $88.06, up $1.17.
BAE Systems share price rises into weekend — what to watch before Monday’s London open

BAE Systems share price rises into weekend — what to watch before Monday’s London open

7 February 2026
BAE Systems shares closed up 1.2% at 1,879 pence on Friday, tracking gains in European defence stocks. The company’s market value stands near £54.8 billion. Investors await BAE’s full-year results on Feb. 18 for updates on cash returns and orders. GXO Logistics renewed and expanded its contract to support BAE’s Type 26 frigate program in Scotland.
Go toTop